CTOs on the Move

Foot & Ankle Specialists of the Mid-Atlantic

www.footandankle-usa.com

 
Need a podiatrist? Foot & Ankle Specialists of the Mid-Atlantic has offices all along the east coast. Contact our doctors today for additional help & information!
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

New Age Medical Center

New Age Medical Center Functional Medicine plays a vital role in our everyday lives and Dr. Moreno is committed to helping our patients achieve improved overall wellness. In addition to internal medicine, anti-aging procedures, and nutritional & wei...

Opiant

Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.

Aegis Therapeutics

Aegis Therapeutics LLC is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nabriva

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria and commenced operations in February 2006. The new organization included small molecule assets, including pleuromutilin structure activity relationships (SAR) knowledge and was focused on synthesis of pleuromutilins for systemic human use. Following identification of our lead compound lefamulin and based on the clinical results of lefamulin for Acute Skin and Skin Structure Infections. We believed that targeted in vitro spectrum of activity for the common pathogens causing Community Acquired Bacterial Pneumonia (CABP), would allow us to develop lefamulin as the first pleuromutilin IV and oral antibiotic for human systemic administration for CABP. In 2014, we opened our US office in King of Prussia, Pennsylvania and completed an IPO on the NASDAQ under the ticker NBRV in September 2015. With net proceeds from our IPO, we initiated two global, registrational Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP. Based on our estimates regarding patient enrollment, we expect to have top-line data available for both trials in the second half of 2017. If the results of these trials are favorable, including achievement of the primary efficacy endpoints of the trials, we expect to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in 2018. As of April 1, 2016, Nabriva employed 52 employees at its headquarters in Vienna, Austria, and its office in King of Prussia, Pennsylvania, United States.

Clinical RM

Clinical RM is a Hinckley, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.